|
Post by parfive on Nov 20, 2014 22:00:02 GMT -5
Yeah, your industry shills are so much more reliable.
Too bad there’s already enough in your Boston Globe link to bury that $2.5B figure in bullshit . . . if you happen to read beyond the first two paragraphs.
|
|
Deleted
Deleted Member
Member since January 1970
Posts: 0
|
Post by Deleted on Nov 20, 2014 22:37:24 GMT -5
You must be referring to this one:
There are far greater costs than actual "out of pocket" to contend with. Things like "opportunity" costs and costs from failed research that also have to be amortized into a balance sheet. To disallow them means either (A) you have never run a business or (B) you have an agenda or (C) all of the above
|
|
|
Post by captbob on Nov 20, 2014 23:01:39 GMT -5
In another 20 years I don't think I will recognize this world. Heck, in another TWO years you won't recognize this COUNTRY.
|
|
gemfeller
Cave Dweller
Member since June 2011
Posts: 3,828
|
Post by gemfeller on Nov 21, 2014 0:38:51 GMT -5
In another 20 years I don't think I will recognize this world. Heck, in another TWO years you won't recognize this COUNTRY. Good Lord, I don't recognize it now!
|
|
|
Post by parfive on Nov 21, 2014 11:33:02 GMT -5
. . . and the pharmaceutical industry funding and . . . the study doesn’t reflect the impact of so-called orphan drug tax credits, in which the US government bankrolls half the cost of clinical trials that qualify, nor does it address research grants from the National Institutes of Health. The NIH funds early-stage research into drug compounds that are eventually sold. Hmm? Tufts methodology uses hundreds of assumptions and estimates and averages . . . wonder why they ignore these? Does one-way street ring a bell? I ain’t buying the “returns investors forgo while a drug is in development” argument either. If I’m an investor and I buy a hundred grand worth of Pfizer, I’m investing in the company, not a drug, and I don’t expect to forgo anything for ten or fifteen years. I will see a dividend paid most every quarter, starting now. (I also doubt there’s a line for “opportunity costs” on the corporate balance sheet.) Yeah, they’re working on a new drug that’s nothing but cost for some number of years, but there’s also an older one that’s all gravy now. Oh, and how could I forget that other one that should’ve gone off patent but they tweaked a shadow and now the gravy’s gonna run for another decade. Off to buy some Weyerhaeuser now so I can bitch cause it takes ten or twenty years to grow a tree and some of ‘em are gonna burn down or get eaten by bugs.
|
|
Deleted
Deleted Member
Member since January 1970
Posts: 0
|
Post by Deleted on Nov 21, 2014 11:59:02 GMT -5
Things like "opportunity" costs and costs from failed research that also have to be amortized into a balance sheet. To disallow them means either (A) you have never run a business or (B) you have an agenda or (C) all of the above I ain’t buying the “returns investors forgo while a drug is in development” argument either. If I’m an investor and I buy a hundred grand worth of Pfizer, I’m investing in the company, not a drug, and I don’t expect to forgo anything for ten or fifteen years. I will see a dividend paid most every quarter, starting now. (I also doubt there’s a line for “opportunity costs” on the corporate balance sheet.) Yeah, they’re working on a new drug that’s nothing but cost for some number of years, but there’s also an older one that’s all gravy now. Oh, and how could I forget that other one that should’ve gone off patent but they tweaked a shadow and now the gravy’s gonna run for another decade. Off to buy some Weyerhaeuser now so I can bitch cause it takes ten or twenty years to grow a tree and some of ‘em are gonna burn down or get eaten by bugs. Yeah, it's both.
|
|
|
Post by parfive on Nov 21, 2014 12:44:23 GMT -5
So I have the agenda here, eh?
I ain’t the one that leaped from a ten-year-old camera on a European satellite to an inflated drug study and a devalued dollar.
|
|
Deleted
Deleted Member
Member since January 1970
Posts: 0
|
Post by Deleted on Nov 22, 2014 11:28:23 GMT -5
So I have the agenda here, eh? I ain’t the one that leaped from a ten-year-old camera on a European satellite to an inflated drug study and a devalued dollar. Thanks for coming out to play.
|
|